By Dr. Charles Kamen, MD — Board-Certified Neurologist
I prescribe GLP-1 medications — semaglutide and tirzepatide — to patients at my Las Vegas practice regularly. These are effective medications that have helped many of my patients achieve meaningful, sustained weight loss. But I would be failing you as a physician if I only told you about the benefits.
Every medication has side effects. GLP-1 receptor agonists are no exception. What matters is understanding which side effects are common and manageable, which are rare but serious, and how to handle them if they arise.
Here is the guide I wish every patient had before starting treatment.
These are the side effects that the majority of patients will experience to some degree, particularly during the dose-titration phase (the first 16-20 weeks when we gradually increase the dose).
How common: 40-50% of patients experience some nausea.
When it occurs: Typically most pronounced in the first 1-2 weeks after each dose increase. Usually improves significantly by week 3-4 at a stable dose.
Why it happens: GLP-1 medications slow gastric emptying — food stays in your stomach longer. This is partially how the medication reduces appetite, but in the early weeks, the change in gastric motility can trigger nausea, especially after large meals.
How I manage it:
When to worry: If nausea is so severe that you cannot keep down fluids for more than 24 hours, or if it is accompanied by severe abdominal pain, contact your physician immediately.
How common: 15-30% of patients.
When it occurs: Can occur at any point during treatment but is most common during dose increases.
Why it happens: GLP-1 medications alter gut motility and can change the composition of the gut microbiome. The resulting shifts in intestinal function can produce loose stools.
How I manage it:
How common: 15-25% of patients.
When it occurs: Can develop gradually as the medication slows gastric motility.
Why it happens: Slower gastric emptying means slower transit through the entire GI tract. Combined with reduced food intake (you are eating less), there is simply less material moving through the system.
How I manage it:
How common: Nearly universal. This is largely the intended effect.
Why I list it as a side effect: Because appetite reduction can become too aggressive in some patients, leading to inadequate nutrition. Patients who eat too little lose muscle mass along with fat, develop nutrient deficiencies, and feel fatigued.
How I manage it:
These affect a smaller percentage of patients but deserve your awareness.
How common: 10-15% of patients.
As a neurologist, I pay special attention to this. Most headaches during GLP-1 therapy are benign — related to dehydration, blood sugar shifts, or caffeine changes (patients who eat less often drink less coffee, triggering caffeine withdrawal).
When I investigate further: If headaches are persistent, severe, or accompanied by visual changes, I evaluate more thoroughly. In extremely rare cases, intracranial pressure changes have been reported with GLP-1 medications, and as a neurologist, I am equipped to assess this.
How common: 10-20% of patients, typically during the first 2-4 weeks.
Why it happens: Your body is adjusting to a new metabolic state. You are consuming fewer calories, and your body has not yet fully adapted to using stored fat for energy. Blood sugar adjustments can also contribute, particularly if you had insulin resistance.
How I manage it: Usually resolves spontaneously. Adequate protein, hydration, and sleep accelerate the adaptation. If fatigue persists beyond 6 weeks at a stable dose, I investigate further — thyroid function, iron levels, and sleep quality are the usual suspects.
How common: 5-10% of patients.
What it looks like: Redness, swelling, or itching at the injection site. Usually mild and self-limiting.
How I manage it: Rotate injection sites (abdomen, thigh, upper arm). Apply ice before injection. If reactions are persistent, we may switch medications.
How common: Reported by 5-10% of patients, typically 3-6 months after starting treatment.
Why it happens: This is almost certainly related to rapid weight loss rather than the medication itself. Significant caloric restriction triggers telogen effluvium — a temporary shift of hair follicles from the growth phase to the resting phase. The same phenomenon occurs after surgery, severe illness, or any rapid weight change.
How I manage it: Ensure adequate protein intake (the most important factor), check iron and vitamin D levels, and reassure patients that this is temporary. Hair regrowth typically begins within 3-6 months. Biotin supplementation has limited evidence, but I do not discourage it.
These require immediate medical attention. They are uncommon, but informed patients are safer patients.
Estimated incidence: Less than 1% of patients.
What to watch for: Severe abdominal pain that radiates to the back, nausea and vomiting that does not resolve, abdominal tenderness. The pain is typically constant and worsened by eating.
My protocol: If a patient reports this symptom profile, we stop the medication immediately and evaluate with lipase levels and imaging. GLP-1 therapy is contraindicated in patients with a history of pancreatitis, which is why thorough screening before starting treatment matters.
Estimated incidence: 1-3% of patients, primarily with rapid weight loss.
Why it happens: Rapid weight loss increases the cholesterol content of bile, promoting gallstone formation. This is a risk with any form of rapid weight loss — surgical, dietary, or pharmaceutical.
What to watch for: Right upper quadrant abdominal pain, especially after fatty meals. Pain that radiates to the right shoulder. Nausea and vomiting associated with these episodes.
My approach: I counsel all patients about gallbladder symptoms before starting treatment. Ultrasound evaluation is warranted if symptoms develop.
The FDA boxed warning: GLP-1 medications carry a boxed warning about medullary thyroid carcinoma (MTC) based on rodent studies. In rats, GLP-1 receptor agonists caused thyroid C-cell tumors at high doses and long exposures.
The human evidence: To date, no causal link has been established in humans. The rodent thyroid has a much higher density of GLP-1 receptors than the human thyroid. Large observational studies have not shown an increased risk of thyroid cancer in patients taking GLP-1 medications.
My approach: I take the boxed warning seriously despite the reassuring human data. GLP-1 therapy is absolutely contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2). For all other patients, I check baseline thyroid function and monitor periodically.
Estimated incidence: Rare, but reported.
Why it happens: Usually secondary to severe dehydration from nausea, vomiting, or diarrhea. Not a direct effect of the medication, but a consequence of inadequate fluid intake during GI side effects.
Prevention: Aggressive hydration. I cannot emphasize this enough, particularly for my patients in Las Vegas where summer heat compounds the dehydration risk. If you cannot keep fluids down, call the office before it becomes an emergency.
There are neurological considerations with GLP-1 therapy that do not get enough attention in the general medical literature.
Some patients report changes in mood — either improvement or, less commonly, worsening of depression or anxiety. GLP-1 receptors are expressed in brain regions involved in mood regulation, and altering GLP-1 signaling can affect serotonin and dopamine pathways.
I screen for mood changes at every follow-up visit. Most patients report improved mood (correlated with weight loss, improved metabolic health, and better sleep). But a small subset experience worsening mood, and this needs to be identified and addressed.
Patients frequently report improved mental clarity and reduced "brain fog" on GLP-1 therapy. This is consistent with the neuroprotective and anti-inflammatory effects of GLP-1 receptor activation. However, patients who eat too little may experience the opposite — cognitive dulling from inadequate caloric intake.
Regulatory agencies have investigated reports of suicidal ideation associated with GLP-1 medications. The data so far has not established a causal link, and the incidence appears no different from the general population. However, I discuss this with all patients, particularly those with a history of depression, and I monitor for it actively.
Based on my clinical experience with hundreds of patients on GLP-1 therapy:
1. Do not rush the titration. The most common cause of severe side effects is escalating the dose too quickly. If your body needs extra time at a particular dose, take it. There is no prize for reaching the maximum dose fastest.
2. Hydrate aggressively. Most side effects are worsened by dehydration. 80+ ounces of water daily. More if you exercise or live in a hot climate.
3. Eat protein, even when you are not hungry. Minimum 60-80 grams daily. This preserves muscle mass, prevents hair loss, and maintains energy levels.
4. Communicate with your physician. Do not suffer in silence through side effects, and do not stop the medication without discussing it first. Most side effects are manageable with simple adjustments. Stopping abruptly can cause rebound hunger and rapid weight regain.
5. Choose a physician who monitors closely. A prescription without follow-up is not treatment. Regular check-ins allow early detection and management of side effects before they become problems.
Every medication decision is a risk-benefit calculation. For patients with obesity — a condition that significantly increases the risk of cardiovascular disease, type 2 diabetes, certain cancers, sleep apnea, joint disease, and neurological decline — the risks of the untreated condition typically far outweigh the risks of GLP-1 therapy.
But this calculation is individual. It depends on your medical history, your risk factors, and your goals. It is a conversation I have with every patient, honestly, before writing any prescription.
If you are considering GLP-1 therapy and want a physician who will be transparent about both the benefits and the risks, I invite you to schedule a consultation at LiveWell21. For a comparison of the two main GLP-1 medications, see my semaglutide vs tirzepatide guide.
You deserve the full picture. Not the sales pitch.
Dr. Charles Kamen is a board-certified neurologist and the founder of LiveWell21 in Las Vegas, Nevada. He earned his MD from Albert Einstein College of Medicine, completed an internship at Yale-New Haven Hospital, and his neurology residency at Loma Linda University.